[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-system-atrophy---parkinsonian-subtype-msa-p\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-system-atrophy---parkinsonian-subtype-msa-p":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,89,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100615197","phase-1-a-phase-iiii-clinical-study-to-evaluate-nouvneu001-injection-for-multiple-system-atrophy-100615197",false,"NCT07289477","A Phase I\u002FIII Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy","A Phase I\u002FIII Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Putamen Transplantation of NouvNeu001 Injection for Multiple System Atrophy","Inclusion Criteria:\n\n* Aged between 30 and 70 years (inclusive), regardless of gender.\n* The subject understands and agrees to comply with the study procedures and voluntarily provides written informed consent.\n* Diagnosed with pathologically confirmed, clinically established, or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria.\n* Current treatments for core MSA symptoms are inadequately controlled.\n* The duration of MSA-related motor symptoms (parkinsonism and\u002For cerebellar ataxia) is no more than 5 years.\n* Ability to walk without human assistance, defined as being able to take at least 10 steps; the use of assistive devices (e.g., a walker or cane) is permitted.\n* Life expectancy of at least 3 years.\n* The subject agrees not to participate in any other clinical studies for 24 months following the investigational product administration.\n\nExclusion Criteria:\n\n* Neurological diseases\u002Fdisorders other than Multiple System Atrophy, such as Parkinson's disease, Dementia with Lewy Bodies, Essential Tremor, Progressive Supranuclear Palsy, Spinocerebellar Ataxia, Hereditary Spastic Paraplegia, Corticobasal Degeneration, Vascular Parkinsonism, Normal Pressure Hydrocephalus, or Drug-induced\u002FPostencephalitic Parkinsonism.\n* Diagnosis of dementia.\n* Previous or current receipt of other disease-modifying therapies, or participation in clinical trials of other new drugs or novel therapies.\n* Use of medications within the past 3 months that may affect Parkinsonian symptoms, autonomic function, or the evaluation of safety.\n* Presence of clinically significant or unstable medical or surgical conditions that may preclude the safe completion of the treatment or confound the treatment outcomes.\n* History of or undergoing treatment for recurrent stroke.\n* Screening brain MRI shows other significant pathological findings, including but not limited to: cerebral hemorrhage, acute cerebral infarction, aneurysm, vascular malformation, infectious lesions, brain tumors, or other space-occupying lesions (meningiomas or arachnoid cysts with a maximum diameter of less than 1 cm do not warrant exclusion).\n* Subjects meeting any of the following criteria indicating advanced disease:\n\nSpeech impairment defined by a score of ≥3 on UMSARS Item 1. Swallowing impairment defined by a score of ≥3 on UMSARS Item 2. Walking impairment defined by a score of ≥3 on UMSARS Item 7. Occurrence of falls more than once per week, defined by a score of ≥3 on UMSARS Item 8.\n\n* History of current substance abuse and\u002For alcohol abuse (within 12 months prior to screening).\n* Known allergy to the investigational product(s); or history of allergy to antibiotics or other drugs.\n* Positive screening results for active viral infection, including Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), Hepatitis B Core Antibodies, or Hepatitis C Virus (HCV).\n* Severe hepatic insufficiency, renal insufficiency, or severe cardiac insufficiency:\n\nSevere hepatic insufficiency: ALT ≥ 2.0 × upper limit of normal (ULN) or AST ≥ 2.0 × ULN.\n\nSevere renal insufficiency: Serum creatinine ≥ 1.5 × ULN or estimated Glomerular Filtration Rate (eGFR) \\\u003C 40 mL\u002Fmin\u002F1.73 m².\n\nSevere cardiac insufficiency: New York Heart Association (NYHA) Class 3 or 4.\n\n* History of thrombocytopenia within the past three months, other bleeding disorders, or current receipt of anticoagulant therapy (excluding aspirin at a dose ≤ 100 mg per day).\n* Pregnancy, lactation, or planning pregnancy.\n* History of Bipolar Disorder, Major Depressive Disorder, Schizophrenia, or other psychotic disorders.\n* Subjects judged by the investigator to have suicidal ideation at screening, or a suicide attempt within 6 months prior to screening.\n* Contraindications for surgery (e.g., implantation of cochlear implants, pacemakers, defibrillators, history of stereotactic ablation, previous implantation of unilateral\u002Fbilateral similar products) or history of other surgeries within the past 6 months deemed by the investigator to potentially affect this trial, or other neurosurgical contraindications.\n* Clinically significant cardiac disease defined as: myocardial infarction, NYHA Class III or IV heart failure, uncontrolled coronary spasm, severe uncontrolled ventricular arrhythmia, or evidence of acute ischemia or abnormal conduction system on ECG within 6 months prior to enrollment.\n* Diagnosis of malignancy.\n* Family history of congenital or inherited immunodeficiency disorders.\n* Considered by the investigator to have poor compliance.\n* Any other significant disease or condition that, in the investigator's judgment, may jeopardize the subject's safety or interfere with the study assessments.","ALL","30 Years","70 Years",{"count":20,"type":21},9,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.",[27],"Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","RECRUITING","2026-04-13",{"date":31,"type":32},"2026-04-14","ACTUAL",{"date":34,"type":32},"2026-01-05",{"date":36,"type":21},"2031-07",{"name":38,"class":39},"iRegene Therapeutics Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":73,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":40},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.",true,"35 Years",{"count":50,"type":21},1000,"OBSERVATIONAL","This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[54,55,56,57,58,59,60,61,62,63,64,65,66,67,27,68,69,70,71,72],"PSP","PSP - Progressive Supranuclear Palsy","Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[74,70,65,75,76,54,62,77,78],"genetic study","Corticobasal","CurePSP","CBD","Genes","2026-01-12",{"date":81,"type":32},"2026-01-14",{"date":83,"type":32},"2024-10-08",{"date":85,"type":21},"2030-12-31",{"name":87,"class":88},"Massachusetts General Hospital","OTHER",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":40},"100586803","epidural-electrical-stimulation-to-support-hemodynamic-management-in-individuals-with-parkinsons-disease-100586803","NCT06920134","Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease","Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Support Hemodynamic Management in People With Typical and Atypical Parkinson's Disease","PD-HemON","Inclusion Criteria:\n\n1. \\> 18 years old\n2. Typical or Atypical PD (including but not limited to Multiple System Atrophy, Pure Autonomic Failure, Progressive Supranuclear Palsy)\n3. Confirmed orthostatic hypotension with a test for verticalization\n4. Confirmed symptomatic orthostatic hypotension that makes daily activities particularly challenging as determined by the study clinicians\n5. Must provide and sign the Informed Consent before any study-related procedures\n6. Stable medical, physical, and psychological conditions given participant indication as considered by Investigators;\n7. Able to understand and interact with the study team in French or English\n8. Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments\n\nExclusion Criteria:\n\n1. Diseases and conditions that would increase the morbidity and mortality of the implantation surgery\n2. The inability to withhold antiplatelet\u002Fanticoagulation agents perioperatively\n3. History of myocardial infarction or cerebrovascular events within the past 6 months\n4. Unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations as determined by the Investigator\n5. History or presence of major psychiatric disorders or major neurocognitive disorders as considered by the Investigators in accordance with the treating physician and treating neurologist\n6. Major changes in PD treatment planned until the end of the main study phase (such as DBS or dopamine-pump implantation)\n7. Inability to follow study procedures.\n8. Spinal anatomical abnormalities precluding surgery\n9. Presence of any indications requiring frequent MRIs.\n10. Current pregnancy or current breastfeeding\n11. Lack of effective or acceptable contraception for women of childbearing capacity\n12. Intention to become pregnant during the study\n13. Unable or unwilling to effectively use the study system or related devices by the participant or caretaker, as determined by the investigator\n14. Participation in another interventional study that might confound study endpoint evaluations\n15. Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons","18 Years","90 Years",{"count":100,"type":21},5,[102],"NA","The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer from orthostatic hypotension.",[105,106,107,66,27],"Hypotension Symptomatic","Parkinson's Disease","Orthostatic Hypotension, Dysautonomic",[109,110,111,112],"orthostatic hypotension","parkinson's disease","autonomic failure","hypotension","2025-11-14",{"date":115,"type":32},"2025-11-18",{"date":117,"type":32},"2025-07-03",{"date":119,"type":21},"2031-05-01",{"name":121,"class":88},"Ecole Polytechnique Fédérale de Lausanne",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":40},"100574934","early-phase-1-the-study-of-safety-and-preliminary-efficacy-of-aleeto-in-patients-with-multiple-system-atrophy-100574934","NCT06765733","The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy","SPRITE","Inclusion Criteria:\n\n1.30 years ≤ 75 years of age, regardless of sex; 2.Clinically confirmed or clinically probable MSA-P; 3.Poor response to levodopa; 4.MSA-related motor symptom onset ≤5 years at first visit; 5.Walking ≥10 meters independently or with a walking aid; 6.Expected survival of ≥1 year, as determined by the investigator; 7.Signed informed consent.\n\nExclusion Criteria:\n\n1. Head MRI at screening showing evidence of other CNS lesions consistent with a diagnosis of neurodegenerative disease other than MSA;\n2. Patients with MMSE scores indicative of dementia prior to enrolment (≤17 points for illiterate individuals, ≤20 points for individuals with elementary school education, ≤24 points for individuals with junior high school education or higher) or those with a prior confirmed diagnosis of dementia;\n3. Head MRI at screening showing other significant pathological findings including but not limited to: cerebral hemorrhage, acute phase of cerebral infarction, aneurysm, vascular malformation, infectious lesion, brain tumor or other space-occupying lesion (meningiomas or arachnoid cysts with a maximum diameter of \\\u003C1 cm need not be excluded);\n4. Presence of immune disorders that are inadequately controlled or require treatment with biological agents;\n5. Known history of allergy to biological agents such as proteins and cell products;\n6. Patients who have received any vaccination within 1 month;\n7. Patients with pre-existing, clearly diagnosed malignant tumor or being treated with anti-tumor drugs;\n8. Patients with a history of clearly diagnosed epilepsy or taking antiepileptic drugs;\n9. Presence of lumbar spine disease and deformity or other contraindications to lumbar puncture;\n10. Patients with abnormal coagulation function prior to enrolment (e.g., platelet count \\\u003C100 × 10E9\u002FL; prothrombin time \\[PT\\] \\>3 s), previous diagnosis of coagulation disorders such as hemophilia, and patients currently receiving more than two types of antiplatelet medication;\n11. Contraindications to MRI (e.g. claustrophobia, internal placement of pacemakers or paramagnetic metals, etc.);\n12. With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value≥2.0 times the upper limit of normal value or AST value≥2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE≥1.5 times the upper limit of normal value or eGFR\\\u003C40mL\u002Fmin\u002F1.73m2; severe cardiac insufficiency refers to NYHA class 3-4);\n13. Hepatitis B active infection (hepatitis B surface antigen positive and\u002For serum HBV DNA positive or serum HBV DNA \\> 2 × 10E8 IU\u002Fml;\n14. Hepatitis C virus antibody positive or history of positive test;\n15. Positive HIV test or history of positive test;\n16. Patients with a combined history of alcohol or drug abuse or alcohol or drug dependence within 2 years;\n17. Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent;\n18. Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant;\n19. Patients who are participating in other interventional studies or using other investigational biological agents, drugs, or devices, and patients who have used other experimental drugs within 1 month or within 5 drug half-lives;\n20. Unable to be cooperative and complete the follow-up due to other reasons.\n21. Patients who, in the opinion of the investigator, are not suitable for participation in this trial.","75 Years",{"count":131,"type":21},20,[133],"EARLY_PHASE1","This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of Aleeto in the treatment of patients with multiple system atrophy (MSA).",[27,136],"Multiple System Atrophy, MSA",[65,138,139,140],"Treatment","Exosomes","Neurorepair","2025-08-30",{"date":143,"type":32},"2025-09-03",{"date":145,"type":32},"2025-05-31",{"date":147,"type":21},"2026-12-31",{"name":149,"class":88},"Beijing Tiantan Hospital"]